Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Cash from Financing Activities (2016 - 2025)

Traws Pharma's Cash from Financing Activities history spans 12 years, with the latest figure at $158000.0 for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $158000.0 for Q4 2025, down 99.21% from a year ago — trailing twelve months through Dec 2025 was $3.2 million (down 91.97% YoY), and the annual figure for FY2025 was $3.2 million, down 90.57%.
  • Cash from Financing Activities for Q4 2025 was $158000.0 at Traws Pharma, up from -$62000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $35.6 million in Q1 2021 to a low of -$62000.0 in Q3 2025.
  • The 3-year median for Cash from Financing Activities is $158000.0 (2025), against an average of $8.7 million.
  • Peak annual rise in Cash from Financing Activities hit 633.77% in 2021, while the deepest fall reached 112.54% in 2021.
  • Year by year, Cash from Financing Activities stood at -$35000.0 in 2021, then soared by 57177.14% to $20.0 million in 2024, then plummeted by 99.21% to $158000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $158000.0, -$62000.0, and $3.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.